Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen

@inproceedings{Zhang2011CrizotinibResistantMO,
  title={Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen},
  author={Sen Zhang and Frank Zhen Wang and Jeffrey A. Keats and Xiaotian Zhu and Yaoyu Ning and Scott D. Wardwell and Lauren E Moran and Qurish K. Mohemmad and Rana Anjum and Yihan Wang and Narayana I. Narasimhan and David C Dalgarno and William Shakespeare and Juan Jos{\'e} Miret and Tim Clackson and V. Rivera},
  booktitle={Chemical biology & drug design},
  year={2011}
}
Activating gene rearrangements of anaplastic lymphoma kinase (ALK) have been identified as driver mutations in non-small-cell lung cancer, inflammatory myofibroblastic tumors, and other cancers. Crizotinib, a dual MET/ALK inhibitor, has demonstrated promising clinical activity in patients with non-small-cell lung cancer and inflammatory myofibroblastic… CONTINUE READING